ATE516503T1 - Auswahl von kopf-hals-krebspatienten für eine behandlung mit arzneimitteln zur anzielung des egfr-pfades - Google Patents

Auswahl von kopf-hals-krebspatienten für eine behandlung mit arzneimitteln zur anzielung des egfr-pfades

Info

Publication number
ATE516503T1
ATE516503T1 AT09774994T AT09774994T ATE516503T1 AT E516503 T1 ATE516503 T1 AT E516503T1 AT 09774994 T AT09774994 T AT 09774994T AT 09774994 T AT09774994 T AT 09774994T AT E516503 T1 ATE516503 T1 AT E516503T1
Authority
AT
Austria
Prior art keywords
head
selection
treatment
cancer patients
neck cancer
Prior art date
Application number
AT09774994T
Other languages
German (de)
English (en)
Inventor
Heinrich Roeder
Maxim Tsypin
Julia Grigorieva
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Application granted granted Critical
Publication of ATE516503T1 publication Critical patent/ATE516503T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Computing Systems (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Software Systems (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Computation (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
AT09774994T 2009-01-20 2009-11-20 Auswahl von kopf-hals-krebspatienten für eine behandlung mit arzneimitteln zur anzielung des egfr-pfades ATE516503T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/321,393 US7867775B2 (en) 2006-03-31 2009-01-20 Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
PCT/US2009/006269 WO2010085235A1 (en) 2009-01-20 2009-11-20 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway

Publications (1)

Publication Number Publication Date
ATE516503T1 true ATE516503T1 (de) 2011-07-15

Family

ID=41559566

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09774994T ATE516503T1 (de) 2009-01-20 2009-11-20 Auswahl von kopf-hals-krebspatienten für eine behandlung mit arzneimitteln zur anzielung des egfr-pfades

Country Status (11)

Country Link
US (1) US7867775B2 (enExample)
EP (1) EP2247954B1 (enExample)
JP (1) JP5025802B2 (enExample)
KR (1) KR101131309B1 (enExample)
AT (1) ATE516503T1 (enExample)
AU (1) AU2009338174B2 (enExample)
CA (1) CA2718113A1 (enExample)
ES (1) ES2368784T3 (enExample)
IL (1) IL211943A (enExample)
TW (1) TWI368737B (enExample)
WO (1) WO2010085235A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
KR101556726B1 (ko) * 2010-02-24 2015-10-02 바이오디식스, 인크. 질량스펙트럼 분석을 이용한 치료제 투여를 위한 암 환자 선별
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
KR102103319B1 (ko) 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
US8718996B2 (en) 2012-07-05 2014-05-06 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
CN112710723B (zh) 2015-07-13 2024-11-12 佰欧迪塞克斯公司 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法
WO2017136139A1 (en) 2016-02-01 2017-08-10 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy
WO2017176423A1 (en) 2016-04-08 2017-10-12 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
WO2018129301A1 (en) 2017-01-05 2018-07-12 Biodesix, Inc. Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
EP3665199A4 (en) 2017-08-07 2021-08-11 Genecentric Therapeutics, Inc. METHOD OF SUBTYPING PLATE EPITHELIAL CARCINOMA OF THE HEAD AND NECK
US20210074431A1 (en) * 2017-08-30 2021-03-11 Genecentric Therapeutics, Inc. Gene expression subtype analysis of head and neck squamous cell carcinoma for treatment management
EP3773691A4 (en) 2018-03-29 2022-06-15 Biodesix, Inc. DEVICE AND METHOD FOR IDENTIFICATION OF PRIMARY IMMUNORESISTANCE IN CANCER PATIENTS
WO2022084993A1 (en) * 2020-10-19 2022-04-28 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Rapid and direct identification and determination of urine bacterial susceptibility to antibiotics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332639D1 (de) 2002-08-06 2010-07-01 Univ Johns Hopkins Verwendung von biomarkern zum nachweis von eierstockkrebs
JP2007506442A (ja) 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
US20050267689A1 (en) 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
US20050048547A1 (en) 2003-07-17 2005-03-03 Hongyu Zhao Classification of disease states using mass spectrometry data
WO2005098445A2 (en) 2004-03-30 2005-10-20 Eastern Virginia Medical School Lung cancer biomarkers
EP2439284B1 (en) * 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7867775B2 (en) 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

Also Published As

Publication number Publication date
IL211943A0 (en) 2011-06-30
EP2247954A1 (en) 2010-11-10
JP5025802B2 (ja) 2012-09-12
TW201028688A (en) 2010-08-01
US7867775B2 (en) 2011-01-11
ES2368784T3 (es) 2011-11-22
TWI368737B (en) 2012-07-21
US20090171872A1 (en) 2009-07-02
AU2009338174B2 (en) 2012-02-02
IL211943A (en) 2014-01-30
KR101131309B1 (ko) 2012-04-02
KR20110047171A (ko) 2011-05-06
AU2009338174A1 (en) 2010-07-29
WO2010085235A1 (en) 2010-07-29
EP2247954B1 (en) 2011-07-13
JP2011513728A (ja) 2011-04-28
HK1148073A1 (en) 2011-08-26
CA2718113A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
TWI368737B (en) Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway
Chuang et al. FAK in cancer: from mechanisms to therapeutic strategies
Nagel et al. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines
Lv et al. EGFR enhances the stemness and progression of oral cancer through inhibiting autophagic degradation of SOX2
Cassell et al. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma
CY1121236T1 (el) Ανθρωπινα αντισωματα εναντι της pcsk9 για χρηση σε μεθοδους θεραπειας συγκεκριμενων ομαδων ατομων
Mittal et al. Recent advances in targeted therapy for glioblastoma
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
CY1111676T1 (el) Μεθοδος για την θεραπεια του καρκινου με αντισταση στην γεφιτινιβη
Sanchez et al. Targeted therapies for the neurofibromatoses
CR9390A (es) Mutaciones del receptor del factor de crecimiento epidermico
UA116665C2 (uk) Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15)
Jacobi et al. ErbB family signalling: a paradigm for oncogene addiction and personalized oncology
JP2011513728A5 (enExample)
Ockenga et al. Epidermal growth factor receptor transactivation is required for mitogen-activated protein kinase activation by muscarinic acetylcholine receptors in HaCaT keratinocytes
Yu et al. Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system in human gastric cancer cells
Simanovich et al. The Anti-EMMPRIN monoclonal antibody hMR18-mAb induces tumor dormancy and inhibits the EMT process in human carcinoma cell lines co-cultured with macrophages
Sahin et al. EGFR signalling and oncogenic pathway signature in colorectal cancer
CN102994640A (zh) 一种检测 VEGFR2 mRNA 基因表达量的试剂盒及方法
Unigwe An Investigation of the Effect of Paclitaxel on Stromal Cells and Collagen Secretion
Koshy et al. Thioredoxin Interacting Protein (TXNIP) Correlates with Production of Reactive Oxygen Species (ROS) and Underlines Differences in Stress Response Gene Profile in Patients with Chronic Lymphocytic Leukemia (CLL).
Lee Lung cancer and insurance medicine
Fox et al. Abstract S3-8: RNAi Screening Identifies the Insulin/Insulin-Like Growth Factor-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Estrogen Receptor-Positive Breast Cancer
Kivioja et al. Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling
Chernichenko et al. The role of Cdc42 in cancer cell perineural invasion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties